AbbVie (NYSE:ABBV) has announced that its two phase 2 trials of a treatment for adults with schizophrenia missed its primary endpoint, sending shares in the drugmaker down sharply in premarket US ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback